SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yu Yang, Yang Du, Wu-Xia Luo, Cong Li, Ye Chen, Ke Cheng, Jing Ding, Yi Zhou, Jun Ge, Xian Yang, Ji-Yan Liu, Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy, Cancer Chemotherapy and Pharmacology, 2015, 75, 4, 783

    CrossRef

  2. 2
    Alok Gupta, Sachin Punatar, Jayant Gawande, Bhausaheb Bagal, Libin Mathew, Vivek Bhat, Sadhana Kannan, Navin Khattry, Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation, Hematological Oncology, 2015, 33, 1
  3. 3
    Ewa Kalinka-Warzocha, Leczenie chorych z chłoniakami i współistniejącym zakażeniem wirusami HCV, HBV lub HIV, Acta Haematologica Polonica, 2015, 46, 2, 86

    CrossRef

  4. You have free access to this content4
    Norah Terrault, Management strategies for hepatitis B–infected patients undergoing immunomodulatory therapy: Is lamivudine enough?, Clinical Liver Disease, 2015, 5, 2
  5. 5
    Jun-Ying Liu, Yun-Jian Sheng, Xiang-Chun Ding, Hui Tang, Shi-Wen Tong, Da-Zhi Zhang, Zhi Zhou, Peng Hu, Yong Liao, Hong Ren, Huai-Dong Hu, The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: A meta-analysis, Journal of the Formosan Medical Association, 2015, 114, 2, 164

    CrossRef

  6. 6
    Emmy Ludwig, HBV reactivation in immunosuppressed patients: Prevention or containment?, Hepatology, 2014, 59, 6
  7. 7
    Xiang-Yuan Wu, Xing Li, Zhan-Hong Chen, Jing-Yun Wen, Qu Lin, Yan-Fang Xing, Min Dong, Li Wei, Tian-Tian Wang, Jie Chen, Ze-Xiao Lin, Xiang-bo Wan, Dan-Yun Ruan, Xiao-Kun Ma, An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study, Tumor Biology, 2013, 34, 2, 909

    CrossRef

  8. 8
    Winnie Yeo, Henry LY Chan, Hepatitis B virus reactivation associated with anti-neoplastic therapy, Journal of Gastroenterology and Hepatology, 2013, 28, 1
  9. 9
    Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao, Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management, Hepatology International, 2013, 7, 2, 316

    CrossRef

  10. You have free access to this content10
    Stanislas Pol, Management of HBV in immunocompromised patients, Liver International, 2013, 33,
  11. 11
    M. Ikeda, Reactivation of Hepatitis B Virus in Patients Receiving Chemotherapy, Japanese Journal of Clinical Oncology, 2013, 43, 1, 8

    CrossRef

  12. 12
    Alexander Kuo, Robert Gish, Chronic Hepatitis B Infection, Clinics in Liver Disease, 2012, 16, 2, 347

    CrossRef

  13. 13
    Amanda Abramson, Alan Menter, Robert Perrillo, Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management, Journal of the American Academy of Dermatology, 2012, 67, 6, 1349

    CrossRef

  14. 14
    H.-R. Li, J.-J. Huang, H.-Q. Guo, X. Zhang, Y. Xie, H.-L. Zhu, L.-Z. Zhai, X.-X. Pu, Y. Huang, C.-C. Guo, T.-Y. Lin, Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy, Journal of Viral Hepatitis, 2011, 18, 12
  15. 15
    Ramazan Idilman, Mutlu Arat, Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation, Expert Review of Anti-infective Therapy, 2011, 9, 8, 641

    CrossRef

  16. 16
    Shih-Hung Tsai, Ming-Shen Dai, Jyh-Cherng Yu, Ching-Liang Ho, Yeu-Chin Chen, Yi-Ying Wu, Ping-Ying Chang, Woei-Yau Kao, Tsu-Yi Chao, Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine, Supportive Care in Cancer, 2011, 19, 11, 1779

    CrossRef

  17. 17
    Masaaki Watanabe, Akitaka Shibuya, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Tsutomu Minamino, Hisashi Hidaka, Takahide Nakazawa, Wasaburo Koizumi, Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients, European Journal of Internal Medicine, 2010, 21, 4, 333

    CrossRef

  18. You have free access to this content18
    John S Lubel, Peter W Angus, Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management, Journal of Gastroenterology and Hepatology, 2010, 25, 5
  19. 19
    Luisa Giaccone, Moreno Festuccia, Andrea Marengo, Isabel Resta, Roberto Sorasio, Fabrizia Pittaluga, Francesca Fiore, Mario Boccadoro, Mario Rizzetto, Benedetto Bruno, Alfredo Marzano, Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, 2010, 16, 6, 809

    CrossRef

  20. 20
    Francesca Cainelli, Sandro Vento, Time for universal HIV and HBV screening for patients with cancer, The Lancet Oncology, 2010, 11, 10, 916

    CrossRef

  21. 21
    Anthony Post, Shweta Nagendra, Reactivation of hepatitis B: Pathogenesis and clinical implications, Current Infectious Disease Reports, 2009, 11, 2, 113

    CrossRef

  22. 22
    Sammy Saab, Melina Yeganeh, Kelvin Nguyen, Francisco Durazo, Steven Han, Hasan Yersiz, Douglas G. Farmer, Leonard I. Goldstein, Myron J. Tong, Ronald W. Busuttil, Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen–positive patients after liver transplantation, Liver Transplantation, 2009, 15, 11
  23. 23
    Lamivudine prophylaxis reduces the risk of HBV reactivation in chemotherapy recipients, Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5, 4, 183

    CrossRef

  24. 24
    Roberto J. Firpi, David R. Nelson, Management of viral hepatitis in hematologic malignancies, Blood Reviews, 2008, 22, 3, 117

    CrossRef